Shilpa Medicare Limited — Important, 27-11-2024: General Updates

Shilpa Medicare's Joint Venture, Oncosol, along with partner Shorla Oncology, has received USFDA approval for IMKELDI (Imatinib oral solution), marking a significant advancement as the first oral liquid formulation of imatinib for treating specific leukemias and other cancers. This advanced formulation aims to address patient adherence issues often associated with imatinib, enhancing accessibility and convenience for treatment. In 2024, approximately 9,280 new cases of chronic myeloid leukemia, over 10,000 cases of myelodysplastic syndrome/myeloproliferative disease, and up to 6,000 cases of gastrointestinal tumors are anticipated in the U.S., underscoring a substantial market opportunity for IMKELDI. This FDA approval positions Shilpa Medicare to capture a critical share of the oncology segment, reflecting a positive outlook ahead.